Letybo 50 Units Powder for Solution for Injection

Letybo

Prescription botulinum toxin type A medicine

Neuromodulator for aesthetic indication (glabellar lines)

Letybo is approved in the UK and EU for cosmetic use in treating glabellar lines and listed among licensed botulinum toxin brands. :contentReference[oaicite:25]{index=25}
FDA approved in the United States for moderate to severe glabellar lines. :contentReference[oaicite:26]{index=26}
Market authorisations granted in multiple European markets by Croma Pharma GmbH. :contentReference[oaicite:27]{index=27}

Letybo is approved in the UK and EU for cosmetic use in treating glabellar lines and listed among licensed botulinum toxin brands. :contentReference[oaicite:25]{index=25}
FDA approved in the United States for moderate to severe glabellar lines. :contentReference[oaicite:26]{index=26}
Market authorisations granted in multiple European markets by Croma Pharma GmbH. :contentReference[oaicite:27]{index=27}

Neuromodulator for aesthetic indication (glabellar lines)

Description

Letybo (letibotulinumtoxinA-wlbg) is a prescription botulinum toxin type A neuromodulator supplied as a white freeze-dried powder for solution for injection. It works by blocking acetylcholine release at neuromuscular junctions, causing temporary muscle relaxation that reduces the appearance of moderate to severe glabellar (frown) lines in adults under 75 years of age. It has received regulatory approvals (e.g., FDA in the United States, UK/EU authorisations) for aesthetic use in glabellar lines. Letybo must be administered only by qualified healthcare professionals trained in neuromodulator injections. :contentReference[oaicite:0]{index=0}

Bnefits

Temporarily improves the appearance of moderate to severe vertical frown (glabellar) lines between the eyebrows. :contentReference[oaicite:1]{index=1}
Provides natural-looking softening of dynamic facial lines by relaxing specific muscle activity. :contentReference[oaicite:2]{index=2}
Offers an alternative to other botulinum toxin products (e.g., Botox, Dysport) with regulatory approvals for aesthetic use. :contentReference[oaicite:3]{index=3}
Clinically studied in Phase III trials (BLESS series) supporting efficacy and safety for glabellar line treatment. :contentReference[oaicite:4]{index=4}

Indications

Temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows (glabellar lines) in adults under 75 years old seen at maximum frown. :contentReference[oaicite:5]{index=5}

Composition

Active substance: botulinum toxin type A (letibotulinumtoxinA-wlbg). :contentReference[oaicite:6]{index=6}
Excipients: human albumin and sodium chloride per regulatory product information in various markets. :contentReference[oaicite:7]{index=7}

Formulation

Freeze-dried (lyophilised) powder for solution for injection in a clear glass vial. :contentReference[oaicite:8]{index=8}
Reconstituted with sterile 0.9% sodium chloride before intramuscular injection. :contentReference[oaicite:9]{index=9}

Packaging

Single-use glass vial containing 50 units of letibotulinumtoxinA powder with a rubber stopper and aluminium tamper-proof seal. :contentReference[oaicite:10]{index=10}
Outer carton containing the vial with package leaflet and professional prescribing information. :contentReference[oaicite:11]{index=11}

Usage

For intramuscular use only by qualified healthcare professionals trained in botulinum toxin injections. :contentReference[oaicite:12]{index=12}
Reconstitute vial with sterile 0.9% sodium chloride using aseptic technique; use immediately after reconstitution. :contentReference[oaicite:13]{index=13}
Administer recommended dose (typically 20 units divided into five injections of 4 units each) into the corrugator supercilii and procerus muscles. :contentReference[oaicite:14]{index=14}
Avoid intravascular injection and follow clinical guidelines for injection technique and patient monitoring. :contentReference[oaicite:15]{index=15}

Contraindications

Hypersensitivity to botulinum toxin type A or to any component of the formulation. :contentReference[oaicite:16]{index=16}
Infection at the injection site(s). :contentReference[oaicite:17]{index=17}
Use in patients with certain neuromuscular disorders may be contraindicated or require caution. :contentReference[oaicite:18]{index=18}

Adverse Effects

Injection-site reactions (e.g., pain, swelling). :contentReference[oaicite:19]{index=19}
Headache. :contentReference[oaicite:20]{index=20}
Eyelid or brow ptosis and eyelid sensory disorders reported in some cases. :contentReference[oaicite:21]{index=21}
Very rare reports of distant spread of toxin effect (e.g., swallowing/breathing difficulties). :contentReference[oaicite:22]{index=22}

Storage Conditions

Unopened vials: store refrigerated at 2–8°C in original packaging protected from light per product labelling. :contentReference[oaicite:23]{index=23}
Do not freeze reconstituted solution; use as specified in the prescribing information. :contentReference[oaicite:24]{index=24}